STgen Bio (formerly DM Bio) is a CDMO specializing in the development and manufacture of mammalian cell culture–based therapeutic proteins and monoclonal antibodies. STgen Bio began as a joint venture between Dong-A Socio Holdings and Meiji Seika Pharma, which both have long histories in the pharmaceutical industries of South Korea and Japan, respectively. Since its founding in 2015, STgen Bio has dedicated itself to matching the specific demands of global biotechnology companies as a one-stop CDMO service with highly qualified experts and state-of-the-art manufacturing facilities.